AccurKardia is redefining ECGs as a more powerful diagnostic tool and broad biomarker, for various disease states including cardiac issues and overlapping conditions! #artificialintelligence J.P. Morgan American Heart Association Heart Rhythm Society #HRX2024 #epeeps #artificialintelligence American College of Cardiology MedTech Innovator LSI MedTech World MedTech Strategist MedTech Startup
AccurKardia’s CEO, Juan C Jimenez will be in San Francisco this coming week! If you’re looking to learn how our technology is redefining ECGs as a more powerful diagnostic tool and broad biomarker, let’s connect. Reach out to [email protected] to schedule a meeting and discover how AccurECG™ (FDA Cleared Class II SaMD), AK-AVS™, and AK+ Guard™ are transforming cardiovascular and renal care. We look forward to meeting you and exploring how we can shape the future of healthcare together! To learn more: AccurECG: https://lnkd.in/eVsubC93 AK-AVS: https://lnkd.in/dYJ6w4JN AK+ Guard: https://lnkd.in/g7CJuTX7